Recent advances in osteoclast biology
- 585 Downloads
The bone is an essential organ for locomotion and protection of the body, as well as hematopoiesis and mineral homeostasis. In order to exert these functions throughout life, bone tissue undergoes a repeating cycle of osteoclastic bone resorption and osteoblastic bone formation. The osteoclast is a large, multinucleated cell that is differentiated from monocyte/macrophage lineage cells by macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL). RANKL transduces its signal through the signaling receptor, RANK. RANKL/RANK signaling activates NFATc1, the master regulator of osteoclastogenesis, to induce osteoclastogenic gene expression. Many types of cells express RANKL to support osteoclastogenesis depending on the biological context and the dysregulation of RANKL signaling leads to bone diseases such as osteoporosis and osteopetrosis. This review outlines the findings on osteoclast and RANKL/RANK signaling that have accumulated to date.
KeywordsOsteoclast RANKL RANK Bone diseases
This work was supported by Ichiro Kanehara Foundation, Lotte Research Promotion Grant, Takeda Science Foundation, The Uehara Memorial Foundation, Japan Agency for Medical Research and Development (AMED, award number: JP17gm0810003), Japan Society for the Promotion of Science (JSPS), Naito Foundation, Astellas Foundation for Research on Metabolic Disorders, Sumitomo Foundation, Asahi Glass Foundation, Daiichi Sankyo Foundation of Life Science, Secom Science and Technology Foundation (SSTF), Mochida Memorial Foundation for Medical and Pharmaceutical Research, Terumo Foundation and Matsui Life Social Welfare Foundation.
- Lum L et al (1999) Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613–13618. https://doi.org/10.1074/jbc.274.19.13613 PubMedCrossRefGoogle Scholar
- Miyamoto H et al (2012) Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell–cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 27:1289–1297. https://doi.org/10.1002/jbmr.1575 PubMedCrossRefGoogle Scholar
- Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N (2002) Receptor activator of NF- B ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22:992–1000. https://doi.org/10.1128/mcb.22.4.992-1000.2002 PubMedPubMedCentralCrossRefGoogle Scholar
- Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768–775. https://doi.org/10.1006/bbrc.2000.3379 PubMedCrossRefGoogle Scholar
- Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752–2756PubMedPubMedCentralCrossRefGoogle Scholar
- Xiao Y, Palomero J, Grabowska J, Wang L, de Rink I, van Helvert L, Borst J (2017) Macrophages and osteoclasts stem from a bipotent progenitor downstream of a macrophage/osteoclast/dendritic cell progenitor Blood Advances. 1:1993–2006 https://doi.org/10.1182/bloodadvances.2017008540
- Yamashita T et al (2007) NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282:18245–18253. https://doi.org/10.1074/jbc.M610701200 PubMedCrossRefGoogle Scholar